IBRX270521C00011000
IBRX May 21 2027 11.00 Call
optionOPRA
EODOct 14, 2026
3.00USD-3.226%(-0.10)14Vol20OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
11
Expiration
May 21, 2027
DTE
213d
Moneyness
OTM
Intrinsic
$0.00
IBRX 11 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.05 | -80.00% | 54 | 1,377 |
| Oct 30, 2026 | 10d | $0.25 | -28.57% | 23 | 2,025 |
| Nov 6, 2026 | 17d | $0.45 | -18.18% | 34 | 379 |
| Nov 13, 2026 | 24d | $0.80 | -20.00% | 9 | 437 |
| Nov 20, 2026 | 31d | $0.55 | -37.50% | 630 | 5,863 |
| Nov 27, 2026 | 38d | $1.02 | +27.50% | 6 | 6 |
| Dec 18, 2026 | 59d | $1.35 | +0.00% | 36 | 21 |
| Jan 15, 2027 | 87d | $1.15 | -32.35% | 392 | 16,123 |
| Mar 19, 2027 | 150d | $1.60 | -41.82% | 11 | 921 |
| Apr 16, 2027 | 178d | $2.48 | -0.80% | 1 | 98 |
| May 21, 2027 | 213d | $3.00 | -3.23% | 14 | 20 |
IBRX Nearby Strikes · May 21, 2027
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.